Difenoxin
An active metabolite of diphenoxylate and opioid-related antidiarrheal agent that reduces intestinal motility by acting on opioid receptors in the gut wall. It is combined with atropine in formulations to discourage abuse. It is used for the symptomatic treatment of diarrhea.
Moleküler Ağırlık
424,5000 g/mol
LogP
2,70
TPSA
64,30 Ų
Lipinski RO5
Geçer
Etki Mekanizması
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …
2D Yapı
Cite this structure
Embed this structure
SMILES
N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1
InChI
InChI=1S/C28H28N2O2/c29-22-28(24-12-6-2-7-13-24,25-14-8-3-9-15-25)18-21-30-19-16-27(17-20-30,26(31)32)23-10-4-1-5-11-23/h1-15H,16-21H2,(H,31,32)
Molecular Formula
C28H28N2O2
HBD / HBA
1 / 4
Döndürülebilir Bağlar
7
Ağır Atomlar
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
An active metabolite of diphenoxylate and opioid-related antidiarrheal agent that reduces intestinal motility by acting on opioid receptors in the gut wall. It is combined with atropine in formulations to discourage abuse. It is used for the symptomatic treatment of diarrhea.
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Yes, Difenoxin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201321. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 34328. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="difenoxin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/difenoxin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/difenoxin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/difenoxin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="difenoxin"></drugfyi-drug>